Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH; Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party. Cheong JW, et al. Among authors: chung j. Transfusion. 2014 Jun;54(6):1542-51. doi: 10.1111/trf.12507. Epub 2013 Dec 3. Transfusion. 2014. PMID: 24313463 Clinical Trial.
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Jang JH, Lee JH, Yoon SS, Jo DY, Kim HJ, Chung J, Lee JW; Korean Society of Hematology Aplastic Anemia Working Party. Jang JH, et al. Among authors: chung j. J Korean Med Sci. 2013 Nov;28(11):1563-72. doi: 10.3346/jkms.2013.28.11.1563. Epub 2013 Oct 31. J Korean Med Sci. 2013. PMID: 24265517 Free PMC article.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Kim DY, et al. Among authors: chung js. Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11. Blood. 2015. PMID: 26065651 Free article. Clinical Trial.
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party. Koh Y, et al. Among authors: chung j. Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24. Ann Hematol. 2010. PMID: 20179930 Clinical Trial.
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Lee SS, et al. Among authors: chung j. Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27. Ann Hematol. 2010. PMID: 20349060 Clinical Trial.
A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
Kim TM, Kim DW, Kang YK, Chung J, Song HS, Kim HJ, Kim BS, Lee JS, Kim H, Yang SH, Yuh YJ, Bae SH, Hyun MS, Jeon YK, Kim CW, Heo DS. Kim TM, et al. Among authors: chung j. Oncologist. 2014 Nov;19(11):1129-30. doi: 10.1634/theoncologist.2014-0305. Epub 2014 Oct 3. Oncologist. 2014. PMID: 25280488 Free PMC article. Clinical Trial.
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization.
Koh Y, Kim DY, Park SH, Jung SH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Shin HJ, Kim SH, Song HS, Chung J, Kim I, Yoon SS, Kim BK, Shin SH, Chung YJ, Park S. Koh Y, et al. Among authors: chung j, chung yj. Cancer Genet Cytogenet. 2010 Dec;203(2):215-21. doi: 10.1016/j.cancergencyto.2010.08.022. Cancer Genet Cytogenet. 2010. PMID: 21156236
12,299 results
You have reached the last available page of results. Please see the User Guide for more information.